- Merck KGaA, Darmstadt, Germany, to assign its Chimeric Antigen Receptor T-cell (CAR-T) rights to Intrexon
- Intrexon to issue Merck KGaA, Darmstadt, Germany, $150 million in Intrexon stock and a $25 million convertible note, and Intrexon to receive a $25 million cash investment
PR Newswire
GERMANTOWN, Md., Dec. 20, 2018